Galderma Group AG Logo

Galderma Group AG

A pure-play dermatology company with aesthetics, skincare, and therapeutic solutions.

GALD | SW

Overview

Corporate Details

ISIN(s):
CH1335392721
LEI:
89450001OK6O8ELQ4584
Country:
Switzerland
Address:
Zählerweg 10, 6300 Zug
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Galderma Group AG is a pure-play pharmaceutical company specializing in dermatology. It operates across the full spectrum of skin health through three main business units: Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. The company develops and markets an innovative, science-based portfolio of premium brands and treatments designed to meet the individual needs of both consumers and patients. Galderma is focused on providing solutions for a wide range of dermatological conditions, positioning itself as a leader solely dedicated to advancing skin health.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Galderma Group AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Galderma Group AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-31 N/A Non-Executive member Sell None 935,664.75 CHF
2025-03-28 N/A Non-Executive member Sell None 1,876,958.07 CHF
2025-03-27 N/A Non-Executive member Sell None 265,440.84 CHF
2025-03-26 N/A Non-Executive member Sell None 673,175.70 CHF
2025-03-25 N/A Executive member Buy None 243,205.38 CHF
2025-03-20 N/A Non-Executive member Sell None 1,156,106.24 CHF
2025-03-20 N/A Non-Executive member Sell None 47,702.12 CHF
2025-03-17 N/A Executive member Sell None 7,962,599.99 CHF
2024-12-20 N/A Non-Executive member Sell None 105,831.00 CHF
2024-11-06 N/A Non-Executive member Sell None 177,500.00 CHF

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.